Key result
Transcatheter edge-to-edge repair plus GDMT reduced death or first heart failure hospitalization at 24 months compared to GDMT alone.
Why the study?
Benefits of transcatheter edge-to-edge repair over guideline-directed medical therapy alone for functional mitral regurgitation have been discordant across randomised trials.
Does transcatheter edge-to-edge repair (TEER) plus guideline-directed medical therapy (GDMT) reduce death or first hospitalisation due to heart failure at 24 months in patients with symptomatic moderate-to-severe functional mitral regurgitation compared to GDMT alone?
Meta-Analysis (n=1,422)
randomized
Does transcatheter edge-to-edge repair (TEER) plus guideline-directed medical therapy (GDMT) reduce death or first hospitalisation due to heart failure at 24 months in patients with symptomatic moderate-to-severe functional mitral regurgitation compared to GDMT alone?
In patients with symptomatic moderate-to-severe functional mitral regurgitation, TEER plus GDMT reduces the composite of death or heart failure hospitalization at 24 months compared to GDMT alone.
Answers are grounded in this paper and cite their sources.
Supports TEER plus GDMT over GDMT alone in symptomatic FMR; extends RCT evidence to 24-month HF outcomes.
BACKGROUND: Transcatheter edge-to-edge repair (TEER) is among the treatments for functional mitral regurgitation (FMR), but its benefits over guideline-directed medical therapy (GDMT) alone are discordant. We conducted a meta-analysis of randomised trials comparing long-term outcomes between these treatment strategies. AIMS: We aimed to compare long-term clinical outcomes between TEER plus GDMT and GDMT alone in symptomatic moderate-to-severe FMR. METHODS: Major electronic databases were searched for randomised trials comparing TEER plus GDMT with GDMT alone in FMR. The primary outcome was death or first hospitalisation due to heart failure at 24 months. The key secondary outcome was first hospitalisation due to heart failure at 24 months. Summary hazard ratios (HRs) with 95% confidence intervals (CIs) were computed by mixed-effects Cox models based on reconstructed time-to-first event individual patient data and random-effects models based on study-level data. RESULTS: Three randomised trials (MITRA-FR, COAPT, and RESHAPE-HF2) were included, for a total of 1,422 patients assigned to TEER plus GDMT (n=703) or GDMT alone (n=719). The primary outcome was significantly lower in the TEER plus GDMT group compared with the GDMT-alone group by one-stage analysis (HR 0.72, 95% CI: 0.56-0.92; p=0.010). However, the two-stage analysis marginally failed to confirm this result (HR 0.72, 95% CI: 0.51-1.00; p=0.052) and showed substantial heterogeneity (I²=80.3%; p=0.006). Hospitalisation due to heart failure was significantly lower in the TEER plus GDMT group, regardless of the statistical method used (one-stage: HR 0.65, 95% CI: 0.48-0.88; p=0.006; two-stage: HR 0.66, 95% CI: 0.45-0.96; p=0.031). However, heterogeneity was substantial (I²=81.2%; p=0.005). All-cause death and cardiovascular death at 24 months were not significantly different between treatment groups but became significant after excluding MITRA-FR in the leave-one-out analysis. CONCLUSIONS: In symptomatic moderate-to-severe FMR, TEER plus GDMT significantly reduces death or hospitalisation due to heart failure and hospitalisation due to heart failure at 24 months.
No takes yet. Share an insight, caveat, or question.
Ammirabile et al. (2026) conducted a meta-analysis in Symptomatic moderate-to-severe functional mitral regurgitation (n=1,422). Transcatheter edge-to-edge repair (TEER) plus guideline-directed medical therapy (GDMT) vs. GDMT alone was evaluated on Death or first hospitalisation due to heart failure at 24 months (HR 0.72, 95% CI 0.56-0.92, p=0.010). Transcatheter edge-to-edge repair plus GDMT reduced death or first heart failure hospitalization at 24 months compared to GDMT alone.
Synapse has enriched 10 related papers. Consider them for comparative context: